Mallinckrodt has agreed to pay $35 million to settle charges of failing to report suspicious orders of controlled substances, the largest such deal involving a drug maker for such an infraction.
The deal also includes what authorities are calling a “groundbreaking parallel agreement” with the Drug Enforcement Agency, which will involve collecting and analyzing data from customers in order to identify suspicious sales.
About the Author Reprints
